PATTERN OF ADVERSE DRUG REACTIONS AND ITS MANAGEMENT IN FEMALE CANCER PATIENTS IN A PRIVATE HOSPITAL IN TELANGANA, INDIA

Authors

  • Kishore P 1Department of Pharmacy Practice, Care College of Pharmacy, Oglapur (v), Damera (m), Warangal,India
  • G Meghana Department of Pharmacy Practice, Care College of Pharmacy, Oglapur (v), Damera (m), Warangal,India
  • B. Pratap Reddy Department of Oncology, St.Ann‟s Hospital, Oglapur (v), Damera (m), Warangal,India
  • K V Raghavaiah Department of Oncology, St.Ann‟s Hospital, Oglapur (v), Damera (m), Warangal,India
  • D Sudheer kumar 3Department of Pharmaceutics, Care College of Pharmacy, Oglapur (v), Damera (m), Warangal,India

DOI:

https://doi.org/10.22270/ajprd.v6i4.381

Keywords:

Adverse drug reaction (ADR), ADR monitoring, Pharmacovigilance, chemotherapy, radiation therapy.

Abstract

ABSTRACT

Chemotherapy and radiation are one of the important components of treatment for many cancers. Anti-neoplastic agents are used with caution due to their high toxicity and narrow therapeutic window. Studies describing pattern of adverse drug reactions in cancer chemotherapy and radiation therapy patients are less in India. This study aims to evaluate the pattern of ADR’s due to cancer chemotherapy and radiation therapy in hospitalized patients and to assess the causality and severity of these reactions in Telangana state, India. This was a prospective observational study conducted in a private hospital in Telangana region from January to august. Two thousand three hundred and forty two ADR’s were recorded from 254 patients. Most common ADR’s were vomiting (10.7 %), nausea (10.7 %) and fatigue (10.7 %). Majority of the ADR’s (53.5 %) were affecting the Gastro-intestinal system. Naranjo scale for causality assessment showed 54.3 % of the reaction to be “definite”, 36.8 % to be “probable”. Modified Hartwig and Siegel scale for severity showed most reaction (84.1 %) to be of “moderate level”, while 13.3 % of reactions were of “mild level”. There is an immediate need to create awareness among health care professionals regarding the importance of the pharmacovigilance system. Use of preventive measures is to be enhanced in order to reduce the incidence and severity of ADR’s. This study showed most ADR’s are preventable with effective ADR monitoring.

Keywords: Adverse drug reaction (ADR), ADR monitoring, Pharmacovigilance, chemotherapy, radiation therapy.

Downloads

Download data is not yet available.

References

1. 1. Mohandas k mallath, David G taylor, Rjendra A Badwe, Goura K Rath, V Shanta, CS Pramesh, Raghunadhara Digumarti, Paul Sebastian et al. The growing burden of cancer in india: epidemiology and social context. 2014(14)70115-9.
2. Rajender A. Badwe, Rajesh dikshit, M.laversanne and Fredie bray. Cancer incidence trends in India. Jpn J Clin Oncol 2014; 44(5)401-407.
3. Sapan Kumar Behera, Chenchu Reddy Kishtapati, Vikneswaran Gunaseelan, Biswajit Dubashi, Adithan Chandrasekaran, Sandhiya Selvarajan. Chemotherapy Induced Adverse Drug Reactions in Cancer Patients in a Tertiary Care Hospital in South India. J Young Pharm, 2017; 9(4): 593-597.
4. Alison Pearce, Marion Haas, Rosalie Viney, Sallie-Anne Pearson, Philip Haywood, Chris Brown, Robyn Ward. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLOS ONE; 2017:10
5. Rajamanickam Baskar, Kuo Ann Lee, Richard Yeo and Kheng-Wei Yeoh. Review Cancer and Radiation Therapy: Current Advances and Future Directions. Int. J. Med. Sci. 2012, International Journal of Medical Sciences 2012; 9(3):193-199.
6. World health organisation. International drug monitoring: the role of the hospital, Geneva: world health organisation; 1996.
7. Jeffery S Russell & A Dimitrios Colevas. Adverse event monitoring in oncology clinical trials- Review: Clinical Trial Methodology; Clin. Invest. 2013; 3(12):1157–1165.
8. Julie Birdie Wahlang, Purnima Devi laishram, Dhriti Kumar Bramha, Chayna Sarkar, Joonmoni Lahon and Banylla Shisha Nongkynrih. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf, 2017; 8(2):61-66.
9. A. Blenkinsopp, P. Winkle, M.Wang and P.A. Routledge. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J clin Pharmacol, 2016; 63:2; 148-156.
10. Mounika M.Review on: Adverse drug reactions of chemotherapeutic drugs. RRJPTS 2016; 4(3).
11. Munir Pirmohamed, Alasdair M Breckenridge, Neil R Kitteringham, B Kevin Park. Adverse drug reactions. BMJ, 1998; 316:25.
12. Ram kumar sahu, rajni yadav, pushpa Prasad, amit roy and shashikant chandrakar. Adverse drug reactions monitoring, prospects and impending challenges for pharmacovigilance. springer plus 2014;3:695.
13. Marília Berlofa Visacri, Cinthia Madeira de Souza, Rafaela Pimente, Cristina Rosa Barbosa. Pharmacovigilance in oncology: pattern of spontaneous notifications, incidence of adverse drug reactions and under-reporting. Brazilian Journal of Pharmaceutical Sciences vol. 50(2); 2014.
14. Kirandeep Kaur, Megha Sood, Shivani Bhagat, Tarundeep Singh, Mukta Jain, Deepty Arora, JS Sekhon, Sandeep Kausha. Spontaneous adverse drug reaction monitoring in oncology: Our experience. Indian Journal of Cancer 2015; 52(3).
15. Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in south India. Br J clin Pharmacol 2008; 65:210-6.
16. Vishal R. Tandon, vivek mahajan, vijay khajuria, zahid gillani. Under reporting of adverse drug reactions: A challenge for pharmacovigilance. Indian journal of pharmacology, 2015; 47 (1).
17. Van Grootheest, A.C.Jong-Van den berg, L.T.W. van. The role and community pharmacists in pharmacovigilance. Res. Social Adm. Pharm., 2005; 1(1); 126-133.
18. Gandhi, T.K.; Bartel, S.B.; Shulman, L.N; Verrier, D.; Burdick, E.; cleary, A.; Rothschidl, J.M.; Leape.; Bates, D.W. Medication safety in ambulatory chemotherapy setting. Cancer, 2005; 104(11):2477-2483.
19. Lau, P.M.; Stewart, K.; Dooley, M.The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support. Care Cancer, 2005; 12(9); 626-633.
20. Cobert, B.L.; Biron P. Pharmacovigilance from A to Z: adverse drug event surveillance. Massachussets: Blackwell Science, 2002; 235.
21. Liekweg, A.; Westfeld, M.; Jaehde, U. From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care- Support. Care Cancer, 200412(2):73-79.
22. Iihara, H.; Ishihara, m.; Matsuura, K.; Kurahashi, S.; Takahashi, T.; Kawaguchi, Y.; Yosida, K.; Itoh, Y. Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J. Eval. Clin. Pract.2011; 18 (4)1-8.
23. Deepti chopra, Harmeet S. Rehan, vibha Sharma, Ritu mishra. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian journal of medical and paediatric oncology 37(1).
24. https://www.cancer.gov/about- cancer /understanding /statistics.
25. Ajitha Sharma, K. Meena Kumar, Hasitha Diana Manohar, K.L.Bairy, Joseph Thomas. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in south India. Perspectives in clinical research April-June 2015; 6(2).
26. Anju Prasad, Pratyay pratim data, Jibak bhattacharya, Chaitali pattanayak, Ashok singh chauhan and Parbaty panda. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in eastern India. J pharmacovigilance 2013;1-2.
27. Hasitha Diana Manohar, Shalini Adiga, Joseph Thomas, Ajitha Sharma. Adverse drug reaction profile of microtubule-damaging antineoplastic drugs: A focused pharmacovigilance study in India. Indian journal of pharmacology, 2016; 48(5).
28. Surendiran. A, N.Balamurgan, K.Gunaselan, Shahid Akhtar, K.S. Reddy, C.Adithan. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol ,2010; 42(40-43).
29. Swapnajaswanth M, suryanarayana S. P., suman G., Murthy N.S. A study to assess select risk factors for carcinoma cervix among patients attending kidwai memorial institute of oncology. Int J Community Med Public Health 2017; 4(11):4238-4243.
30. Ann M. Berger. NCCN clinical practice guidelines in oncology guidelines for cancer related fatigue. 2017

Published

2018-08-23

How to Cite

P, K., Meghana, G., Reddy, B. P., Raghavaiah, K. V., & kumar, D. S. (2018). PATTERN OF ADVERSE DRUG REACTIONS AND ITS MANAGEMENT IN FEMALE CANCER PATIENTS IN A PRIVATE HOSPITAL IN TELANGANA, INDIA. Asian Journal of Pharmaceutical Research and Development, 6(4), 45–53. https://doi.org/10.22270/ajprd.v6i4.381

Issue

Vol. 6 No. 4 (2018): VOLUME 6 ISSUE 4 JULY - AUGUST 2018

Section

Research Articles

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).